Jay Bradner, Amgen EVP of R&D (Jeff Rumans Photography)
Amgen announces hold on Phase 1 obesity candidate, pipeline cuts
Amgen said one of its early-stage obesity programs has been put on a clinical hold by the FDA, while reiterating its ambitions to become a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
